Common Contracts
9 similar Exclusive License Agreement contracts by Atara Biotherapeutics, Inc.
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and SANTA MARIA BIOSCIENCES, INC. Dated as of September 7, 2012Exclusive License Agreement • July 10th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of September 7, 2012 (the “Signing Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and SANTA MARIA BIOSCIENCES, INC., a Delaware corporation (“Company”). Company and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and NINA BIOSCIENCES, INC. Dated as of September 7, 2012Exclusive License Agreement • July 10th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and PINTA BIOSCIENCES, INC. Dated as of September 7, 2012Exclusive License Agreement • July 10th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of September 7, 2012 (the “Signing Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and PINTA BIOSCIENCES, INC., a Delaware corporation (“Company”). Company and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and SANTA MARIA BIOSCIENCES, INC. Dated as of September 7, 2012Exclusive License Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of September 7, 2012 (the “Signing Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and SANTA MARIA BIOSCIENCES, INC., a Delaware corporation (“Company”). Company and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and PINTA BIOSCIENCES, INC. Dated as of September 7, 2012Exclusive License Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of September 7, 2012 (the “Signing Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and PINTA BIOSCIENCES, INC., a Delaware corporation (“Company”). Company and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and NINA BIOSCIENCES, INC. Dated as of September 7, 2012Exclusive License Agreement • June 20th, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and PINTA BIOSCIENCES, INC. Dated as of September 7, 2012Exclusive License Agreement • May 22nd, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of September 7, 2012 (the “Signing Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and PINTA BIOSCIENCES, INC., a Delaware corporation (“Company”). Company and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and SANTA MARIA BIOSCIENCES, INC. Dated as of September 7, 2012Exclusive License Agreement • May 22nd, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of September 7, 2012 (the “Signing Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and SANTA MARIA BIOSCIENCES, INC., a Delaware corporation (“Company”). Company and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and NINA BIOSCIENCES, INC. Dated as of September 7, 2012Exclusive License Agreement • May 22nd, 2014 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
